Yang et al. reported results on 23 ESCC patients with stage II or III resectable ESCC undergoing neoadjuvant treatment with camrelizumab, nab-paclitaxel and carboplatin before surgery: 25% of the patients had a pCRR, and 50% had a major pathological response; the patients with a high tumor mutation burden and high expression of PD-L1 were more frequently in the pCRR group than the non-pCRR group [122]. Here, CD274 is linked to neoplasm.